# NEXT DTP-23-017, PRODUCTION OF 0.25MG OF AZATDC AND TDCYD CAPSULES

> **NIH NIH N02** · IRISYS, INC. · 2023 · $66,182

## Abstract

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) develops cancer therapeutic agents under the Developmental Therapeutics Program (DTP). Part of the DTP services includes formulation and production of clinical dosage forms of the agents selected by DCTD for further development.

The Objective of this Task Order is to provide manufacturing of a batch sufficient to deliver 800 capsules containing 0.25 mg Aza-TdC per capsule and 2500 capsules containing 0.25 mg TdCyd per capsule.

## Key facts

- **NIH application ID:** 10948447
- **Project number:** 75N98019D00058-0-759102300001-1
- **Recipient organization:** IRISYS, INC.
- **Principal Investigator:** ROBERT GIANNINI
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $66,182
- **Award type:** —
- **Project period:** 2023-04-18 → 2023-07-17

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10948447

## Citation

> US National Institutes of Health, RePORTER application 10948447, NEXT DTP-23-017, PRODUCTION OF 0.25MG OF AZATDC AND TDCYD CAPSULES (75N98019D00058-0-759102300001-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10948447. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*